The QualityStocks Daily Tuesday, August 21st, 2018

Today's Top 3 StockMarketWatch

StreetInsider (CVSI) +32.50%

BUYINS.NET (JG) +23.40%

StockMarketWatch (LLEX) +19.76%

The QualityStocks Daily Stock List

Dajin Resources Corp. (DJIFF)

Investing News, Stockhouse, Streetwise Reports, Junior Mining Network, InvestorsHub, 4-Traders, GuruFocus, Epstein Research, StockInvest, Barchart, Wall St. Researcher, Wallet Investor, Equities, Marketwired, OTC Markets, TradingView, Investx, Dividend Investor, and MarketWatch reported on Dajin Resources Corp. (DJIFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dajin Resources Corp. is a lithium exploration company listed on the OTC Markets Group’s OTCQB. Via its interest in Dajin Resources S.A. (Dajin S.A.), the Company holds concessions or concession applications in Jujuy Province, Argentina. These were acquired in areas known to contain brines with Lithium, Potassium and Boron values. Dajin Resources has its corporate office in Vancouver, British Columbia.

The aforementioned land holdings exceed 93,000 hectares (230,000 acres). They are mainly located in the Salinas Grandes and Guayatayoc salt lake basins.  Dajin Resources projects include Teels Marsh, Alkali Lake, and Salinas Grandes.

The Teels Marsh Lithium Project in Nevada is 3,202 hectares - 7,914 acres. There are 403 placer claims. Teels Marsh is 100 percent owned by Dajin Resources (US) Corp., which is a wholly-owned subsidiary of Dajin Resources Corp. Construction of drill pads and roads is completed in expectation of starting a drill program later in 2018.

The Alkali Lake Lithium Project in Nevada is 2,262 hectares - 5,591 acres. There are 278 placer claims. Alkali Lake is 100 percent owned by Dajin Resources (US) Corp.

The Salinas Grandes Project in Argentina is 93,000 hectares - 230,000 acres. There are 25 concessions. Salinas Grandes is 100 percent owned by Dajin Resources S. A., which is a wholly-owned subsidiary of Dajin Resources Corp. This past February, Dajin announced the results of 25 shallow brine samples encompassing an area of 550 hectares (5.5 km2) in the northwestern corner of the 4,300-hectare (43 km2) San Jose and Navidad minas.  Concentrations ranged from 281 mg/l to 1,353 mg/l, averaging 591 mg/l Lithium.  A drill program for the San Jose and Navidad minas is now being organized.

Last week, Dajin Resources management reported that the Company’s engineers, Welsh Hagen Associates, Inc. (Reno, Nevada), completed the construction of access roads and drill pads at Dajin’s 100 percent owned, Teels Marsh Lithium brine project in Mineral County, Nevada. Welsh Hagen provided the design, prepared the BLM Notice of Intent and construction services for Dajin.  Tipton Trucking of Mina, Mineral County, Nevada, Coan Equipment and MB America both of Reno, Nevada supplied the construction equipment.

Dajin Resources Corp. (DJIFF), closed Tuesday's trading session at $0.078, down 0.65%, on 140,500 volume with 16 trades. The average volume for the last 60 days is 94,203 and the stock's 52-week low/high is $0.06/$0.1731.

chart

TSS, Inc. (TSSI)

RedChip, Marketbeat.com, and Wall Street Resources reported on TSS, Inc. (TSSI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, TSS, Inc. is a data center and mission critical facilities and technology services enterprise. The Company is a single source provider of mission-critical planning, design, system integration, deployment, maintenance, and development of data centers facilities and information infrastructure. TSS is an innovator in the hyper-dynamic mission-critical facilities industry. The Company is based in Round Rock, Texas.

TSS is an innovator and leader in mission-critical infrastructure design and support services. These include Modular Data Centers, Assessments & Audits, Design & Budgeting, Project & Construction Services, Operations & Maintenance, and Planning & Analysis or Transformation Services. Its Data Center Services include Modular Data Centers; Data Center Health Check; Facility Assessment; Owners Representation; Strategic Options Analysis; CFD Assessment; Data Center Transition Planning; Information Technology (IT) Equipment Relocation Services; and Arc Flash-Hazard Analysis.

TSS has worked across numerous industries. The Company has planned, designed, built, as well as maintained specialized facilities. These include data centers, communications rooms, SCIFs, call centers, laboratories, trading floors, network operations centers, and medical facilities.

The Company provides a single-source solution for mission-critical facilities. It specializes in customizable end-to-end solutions powered by industry experts and creative services. These include technology consulting, engineering, design, project management, operations, facilities management, technology system installation and integration, and maintenance for traditional and modular data centers.

TSS integrates a facility’s electrical, mechanical, security, and building envelope into a unified strategic asset. The Company’s goal is to provide its customers with the most advanced and reliable mission-enabling solutions. Its expertise is in IT and integrated facilities services. The Company provides end-to-end solutions for all facets of a client’s critical facility projects.

An example of TSS’s solutions is the above-mentioned Modular Data Centers (MDCs). The Company provides MDC solutions, which help customers’ to cost-effectively design and deploy a data center founded on quality, scalability, maintainability, and portability. TSS can provide a customer with design, engineering, installation, and maintenance services to configure and support solutions unique to their requirements.

Concerning MDC Pre-Deployment, the Company offers Site Assessment, Site Design, and IT Integration. Regarding Deployment, it offers Site Preparation; Receiving; Rigging; Assembly/Connections; and Commissioning. Concerning Post-Deployment, it offers Warranty and Preventative Maintenance & Break/Fix Services. Today, (Monday, August 14, 2017) TSS reports its financial results for Q2 of 2017.

TSS, Inc. (TSSI), closed Tuesday's trading session at $0.62, up 0.08%, on 6,100 volume with 5 trades. The average volume for the last 60 days is 9,682 and the stock's 52-week low/high is $0.141/$0.65.

chart

NaturalShrimp, Inc. (SHMP)

ThePennyPicks, PennyPickGains, SmallCapVoice, Pennystockmania, and WallstreetSurfers reported on NaturalShrimp, Inc. (SHMP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

NaturalShrimp, Inc. is a global leader in aquaculture technology. The Company has developed and tested the first commercially-viable system for growing shrimp indoors. This system utilizes a proprietary technology to reliably produce healthy, naturally-grown shrimp weekly without the use of antibiotics or toxic chemicals. OTCQB-listed, NaturalShrimp is headquartered in La Coste, Texas.

NaturalShrimp, Inc. owns 100 percent of NaturalShrimp Corporation, created to operate in the U.S. and Canada, and 100 percent of NaturalShrimp Global, Inc., established to create International Joint Venture (JV) Partnerships. The Company’s production facility is outside of San Antonio, Texas. Its European partner has built a production facility in Medina del Campo, Spain. Expansion plans include domestic and international production facilities and distribution channels.

NaturalShrimp has developed a technology to produce fresh, gourmet-grade shrimp dependably and economically in an indoor, re-circulating, saltwater facility. The Company’s eco-friendly, bio-secure design does not rely on ocean water. It recreates the natural ocean environment allowing for high-density production that can be replicated anywhere in the world.

The NaturalShrimp Automated Monitoring and Control system employs individual tank monitors to automatically control the feeding, the oxygenation, as well as the temperature of each of the facility tanks independently. Furthermore, a facility computer, running custom software, communicates with each of the controllers and performs additional data acquisition functions, which can report back to a supervisory computer from anywhere in the world. The computer automated water controls optimize the growing conditions for the shrimp as they mature to harvest size. This provides a disease-resistant production environment.

NaturalShrimp, along with its technology partner F&T Water Solutions, LLC, has teamed with Filtertech, Inc. on manufacturing the production equipment package to initially be deployed at NaturalShrimp’s La Coste facility. The proprietary equipment package is the foundation of the Company’s patented technology. The equipment covers NaturalShrimp’s base process of growing healthful, naturally grown shrimp without the use of chemicals and/or antibiotics.

Last month, Natural Shrimp announced that it is currently working with the HART team in supplying waste data for the creation of a formal shrimp aquaculture solution. Gray CC Ventures, Strategic Sustainable Support (S3), BCH Sustainable Energy Partners, and Trane have been developing a best-practices quality framework named HART (Humane, Accountable and Renewable Technologies), for the agriculture livestock industry. Each of the participating team members is responsible for a particular part of the program. This includes diet, humane care and harvesting of the livestock, engineering, and waste-to-energy (the conversion of waste products into useful commodities, including pet food feedstock, compost, and renewable energy).

Mr. Gerald Easterling, NaturalShrimp’s President, said, "We are excited to be assisting the HART team in the aquaculture arena. As aquaculture grows over the next several years, it is important that it continues to support the long term viability of the environment. We have over 16 years of data that has been recorded since our inception in 2001. This information should prove invaluable to the team."

NaturalShrimp, Inc. (SHMP), closed Tuesday's trading session at $0.0179, up 8.48%, on 888,725 volume with 30 trades. The average volume for the last 60 days is 1,009,686 and the stock's 52-week low/high is $0.01/$1.00.

chart

Marathon Gold Corporation (MGDPF)

Stockhouse, 4-Traders, TipRanks, MarketWatch, TradingView, The Street, Resource World, WalletInvestor, StockInvest, Stockwatch, YCharts, Streetwise Reports, Barchart, Penny Stock Hub, Mining.com, Capital Equity Review, OTC Markets, Marketbeat, and Investors Hangout reported on Marathon Gold Corporation (MGDPF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

A gold exploration Company, Marathon Gold Corporation is quickly advancing its 100 percent owned Valentine Lake Gold Camp in Newfoundland. Currently, the Valentine Lake Gold Camp hosts four near-surface, mainly pit-shell constrained deposits with measured and indicated resources totaling 2,137,400 oz. of gold at 1.99 g/t and inferred resources totaling 1,104,700 oz. of gold at 1.99 g/t. Most of the resources occur in the Marathon and Leprechaun deposits, which also have resources below the pit shell.  Both deposits are open to depth and on strike. Marathon Gold is headquartered in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQX.

The Valentine Lake Gold Camp is accessible by year-round road. It is in close proximity to Newfoundland’s electrical grid. Recent metallurgical tests have demonstrated 93 percent to 98 percent recoveries via conventional milling and 50 percent to 70 percent recoveries via low cost heap leaching at the Leprechaun and Marathon Deposits.

Drilling in 2018 continues to center on expanding the Marathon Deposit at surface and to depth and also exploration drilling along the boggy covered area between the Marathon and Sprite Deposits. Gold mineralization has been traced down over 350 meters vertically at Leprechaun and close to a kilometer at Marathon.

The four deposits outlined so far occur over a 20-kilometer system of gold bearing veins. Much of the 24,000-hectare property has had little detailed exploration activity so far. Marathon’s exploration projects include Baie Verte (100 percent owned - Newfoundland) and the Bonanza Mine (100 percent owned – Oregon).

This past May, Marathon Gold completed its initial PEA (Preliminary Economic Assessment) on the Valentine Lake project. This is the first economic study undertaken at Valentine Lake.

The Company stated that the results of the study were very encouraging and positive, confirming a potential mining operation involving heap leaching and conventional processing, producing 188,500 ounces of gold annually for the first 10 years of its life at an all-in sustaining cost (AISC) of US$595 per ounce and generating a pre-tax IRR (Internal Rate of Return) of 34 percent and an after-tax IRR of 25 percent on estimated pre-production costs of US$380 million.  The expectation is that the project will produce an after-tax NPV (Net Present Value- 5 percent) of US$367 million (CAD$466 million) for an 11-year mine life. The after-tax payback period is 2.8 years.

In late July, Marathon Gold announced the intersection of high-grade gold mineralization at depth within the main corridor of the Marathon Deposit. MA-18-295 was very successful in intersecting a broad interval of high grade gold in en-echelon stacked QTP veining, which returned 7.97 g/t Au over 59.0 meters including 57.74 g/t Au over 5.0 meters, 48.12 g/t Au over 2.0 meters, and 27.81 g/t Au over 1.0 meter. This drill hole was part of the current continuing infill drilling program at the Marathon Deposit designed to upgrade inferred material into the measured and indicated category.

Marathon Gold Corporation (MGDPF), closed Tuesday's trading session at $0.6439, down 0.94%, on 20,720 volume with 13 trades. The average volume for the last 60 days is 31,421 and the stock's 52-week low/high is $0.6346/$1.0318.

chart

Blox, Inc. (BLXX)

OTC Markets Group, SmallCapVoice, and PennyStocks24 reported earlier on Blox, Inc. (BLXX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Blox, Inc.’s vision is to pioneer the development of mining projects through applying green innovation to traditional mining methods and combining renewable energy and technology into the process. The OTCQB-listed Company’s plan is to become an international leader in the production of “green minerals”. Blox Minerals is a wholly-owned subsidiary of Blox, Inc. Blox is based in Vancouver, British Columbia.

An important element of Blox’s mandate is to implement clean energy into the mining process. This is to effectively “green” the mining process and minimize its environmental impact via lower hydrocarbon emissions. The Company’s plan is to build a portfolio of gold and other minerals and produce them in a socially and environmentally friendly manner.

Blox defines “green minerals” as minerals produced using technologies, best practices, and mine processes implemented to reduce the environmental impacts associated with the extraction and processing of metals and minerals. Its plan is to use renewable energy and technology in the production of green minerals with the goal of turning expensive costs into profits through utilizing renewable energy plants to power its different projects.

Blox’s key concession holdings are in Ghana and Guinea, West Africa. Its projects include Pramkese, Osenase, Asamankese, and Mansounia.

The Mansounia Exploration Licence is centered on Latitude 10º 23’ N and Longitude 9º 47’ W in the Kouroussa Prefecture, Kankan Region, in Guinea, West Africa. It covers a surface area of 145 square kms. At Mansounia, significantly fresh rock mineralization has been intersected and as of July 2016, remains unexplored. Mansounia is a priority development asset for Blox.

Blox has entered into a Strategic Alliance Agreement with Ashanti Sankofa, Inc.  With the terms of the Strategic Alliance Agreement, both parties agreed to grant to the other party a right of first refusal to enter into a joint venture (JV) on any of their respective properties and/or projects and that any future acquisition of natural resource properties that may be acquired by either party that contains, but is not limited to, gold, precious metals, technology metals or diamonds (Natural Resource Properties), the acquiring party will grant to the other party a right of first refusal to participate in a JV on such Natural Resource Property that shall be at the sole discretion of the acquiring party.

In July, Blox announced that a new drilling target was defined by a 2.5km long Gold in Soil anomaly, at its Mansounia Gold Project, in the highly prospective Siguiri Basin area of Eastern Guinea. This new drilling target was defined after a wide-ranging database compilation and exploration targeting exercise undertaken by Sahara Natural Resources on the historical data held by Blox in the region. Sahara defined a Gold in Soil geochemical anomaly over roughly a 2.5km strike. The anomaly is open and untested to the North and South.

Blox, Inc. (BLXX), closed Tuesday's trading session at $0.23, even for the day. The average volume for the last 60 days is 511 and the stock's 52-week low/high is $0.071/$0.30.

chart

Security Devices International, Inc. (SDEV)

YCharts, Zacks, MarketWatch, Stockhouse, OTC Markets, and InvestorsHub reported on Security Devices International, Inc. (SDEV), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Security Devices International, Inc. (SDI) specializes in the areas of Military, Law Enforcement, Corrections, and Private Security. A technology enterprise, the Company develops and manufactures innovative, less lethal equipment and munitions. OTCQB-listed, SDI has its U.S. office in Wakefield, Massachusetts. It has a Canadian office in Burlington, Ontario.

SDI is shifting its focus to a Licensing model. The licensing of its intellectual property (IP) will be an important aspect of its strategy going forward. The Company is working to sign agreements with strong partners around the world, which have first-rate manufacturing capabilities and large distribution networks.

The Company specializes in the development, manufacturing, and sale of next-generation 40mm less lethal ammunition. The design of its Family of Blunt Impact Projectiles (BIP) are for military, peacekeeping, homeland security, law enforcement, correctional services, and private sector security. They are ideal for crowd control scenarios. Furthermore, they are adaptable to any 40mm caliber standard issue weapons and grenade launchers.

The development of SDI’S patented rounds has been for accuracy at longer ranges. This is to ensure the greater safety of the user. They provide an effective way of incapacitating subjects without causing lethal injury. This is due to the unique design of the BIP. The design utilizes a unique collapsible head to mitigate kinetic energy. Consequently, this makes it highly effective even at a very close range.

The Company has also designed a Wireless Electric Projectile (WEP). It employs mini-harpoons to affix a bullet to a target’s clothing or body. SDI also has its SDI Instructor Training Course. This course provides professionally skilled instructors in less lethal for the military, law enforcement, correctional services, homeland security, and private sector security personnel.

This past April, SDI announced its acquisition of patents and related Intellectual Property (IP) centered on a new less lethal platform. This platform delivers chemical irritants from a handgun-like Personal Security Device (PSD).

As its initial product offering using the new IP, SDI is planning the introduction of a small, light-weight, .68 caliber hand-held PSD equipped with a 7-round magazine and capable of accurately and effectively engaging a target at up to 60 feet - less lethally and without causing serious injury.

Security Devices International, Inc. (SDEV), closed Tuesday's trading session at $0.15, even for the day, on 3,000 volume with 2 trades. The average volume for the last 60 days is 18,765 and the stock's 52-week low/high is $0.11/$0.1852.

chart

Magellan Gold Corp. (MAGE)

Penny Stock Pick Alert, RisingPennyStocks, SixFigureStockPicks, Greenbackers, PennyPickAlerts, PennyStockMoneyTrain, Pumps and Dumps, FOX Penny Stocks, Joe Penny Stocks, Liquid Tycoon, Penny Stock Pick Report, Super Hot Penny Stocks, Super Nova Stock Picks, WePickPennyStocks, and Winning Penny Stock Picks reported on Magellan Gold Corp. (MAGE), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Magellan Gold Corp.’s primary business is the acquisition and exploration of mineral resources. The OTCQB-listed Company engages in the acquisition and exploration of precious metals mineral properties. Its updated strategic goal is building a mid-tier precious metals exploration and mining company.  Magellan Gold is headquartered in Vacaville, California.

Magellan has its "Silver District" project. This project consists of 94 unpatented lode mining claims, 6 patented lode claims, an Arizona mining lease of 335 acres, and 23 unpatented mill site claims, totaling greater than 2,000 acres. Magellan Gold holds its properties via its 85 percent owned subsidiary Gulf & Western Industries, Inc.

Its district-scale property position encompasses the core of the historic Silver District in La Paz County, about 50 miles north of Yuma. At the Silver District Project in southwest Arizona, the Company’s goal is to expand its resource base containing an historic resource of 16 million ounces of silver. It also plans to acquire additional advanced-stage properties that have tangible promise for development.   

Magellan Gold has the right to earn an undivided 50 percent interest in the Niñobamba Silver/Gold Project in central Peru. To earn its 50 percent interest, the Company must spend $2.0 million in exploration over three years. The Niñobamba project covers 9,027 acres and demonstrates potential for a large, bulk tonnage, silver-gold deposit.

Rio Silver and its project partner, Magellan Gold, announced this past February that they initiated exploration work on the expanded Niñobamba Project. Recent strategic additions to the land package have created a large, contiguous property comprising 3100 hectares and another 553-hectare concession pending title confirmation. Magellan Gold will be spending US$2 million at the Niñobamba project to earn its 50 percent interest.

This past March, Magellan Gold announced that it entered into a Memorandum of Understanding (MOU) with Rose Petroleum plc to purchase an operating floatation plant, which also includes a precious metals leach circuit and associated assets, licenses and agreements (together, the SDA Mill), located in the State of Nayarit, Mexico, for a total consideration of US$1.5 million. The basis of the mill's normal operation is on sales of floatation concentrates to smelters, and payment for precious metals content. The mill currently engages in toll milling for third party ore producers. Rose Petroleum is a multi-asset natural resource enterprise.

This week, Magellan Gold announced it arranged $900,000 in irrevocable bridge loans in support of its option to purchase the SDA Mill from Rose Petroleum. The bridge loans are enough to complete the cash component of the purchase price and have the effect of extending the purchase option until closing of the transaction.

To extend the option, Magellan Gold had the obligation to secure the bridge loans on or before August 15, 2017. Total consideration for the purchase is US $1.5 million, comprising $1.0 million in cash and $500,000 in Magellan stock, of which $100,000 in cash already was paid.

Magellan Gold Corp. (MAGE), closed Tuesday's trading session at $0.029, up 18.13%, on 59,491 volume with 7 trades. The average volume for the last 60 days is 58,288 and the stock's 52-week low/high is $0.012/$0.0995.

chart

Sun BioPharma, Inc. (SNBP)

Beacon Equity Research, AllPennyStocks, TheStockWizards, The Dean, FeedBlitz, MicrocapVoice, AheadoftheBulls, Today's Financial News, HotPennyStocksNow, OTC Picks, Hot Shot Stocks, Wall Street Resources, Greenbackers, CoolPennyStocks, Otcstockexchange, HotOTC, and Lebed reported previously on Sun BioPharma, Inc. (SNBP), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Sun BioPharma, Inc. is a Biopharmaceutical Company listed on the OTC Markets’ OTCQB. It is developing disruptive therapeutics for the treatment of patients with pancreatic diseases. A clinical-stage biopharmaceutical company, Sun BioPharma’s development programs target diseases of the pancreas. This includes pancreatic cancer and pancreatitis. Sun BioPharma has its head office in Waconia, Minnesota.

The Company’s initial product candidate is SBP-101. This product is for the treatment of patients with pancreatic cancer. Mr. Ray Bergeron, Ph.D. Distinguished Professor Emeritus, University of Florida invented SBP-101. Sun BioPharma’s plan is to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, the most common kind of pancreatic cancer.

SBP-101 is a first-in-class, proprietary, polyamine compound. The design of it is to exert therapeutic effects in a mechanism specific to the pancreas. The Company originally licensed SBP-101 from the University of Florida in 2011.

In addition, the Company’s SBP-102 is currently in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. Furthermore, Sun BioPharma’s SBP-103 is now in non-clinical exploratory evaluation.

Sun BioPharma has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, California; the University of Miami; the University of Florida; the Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia, and the Ashford Cancer Centre in Adelaide, Australia.

Sun BioPharma previously announced the completion of the first-in-human safety study of SBP-101 in previously treated patients with pancreatic ductal adenocarcinoma (PDA). SBP-101 was well tolerated. Moreover, signals of efficacy were observed at dose levels below the Maximum Tolerated Dose (MTD).

Sun BioPharma’s newest trial, a Phase 1a/1b combination of SBP-101 to be administered with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA), enrolled the first patients on June 13, 2018. Patients were enrolled at the Adelaide Cancer Centre in Adelaide, Australia under the direction of Associate Professor Dusan Kotasek and at the University of Florida Health Cancer Center in Gainesville, Florida under the direction of Thomas J. George, MD, F.A.C.P.

The Phase 1a portion of the study will treat up to 18 PDA patients in three cohorts to ascertain a recommended dose of SBP-101 to be given in combination with standard treatment. Suzanne Gagnon, MD, Chief Medical Officer for Sun BioPharma, said, “The Company and our investigators are excited to have begun this first cohort of patients in the Phase 1a portion of this study. The clinics are enthusiastic about utilizing SBP-101 in front-line combination for previously untreated patients with metastatic PDA. We all will be closely monitoring these patients as they move through the protocol for this study.”

Sun BioPharma, Inc. (SNBP), closed Tuesday's trading session at $4.00, up 1.27%, on 503 volume with 3 trades. The average volume for the last 60 days is 692 and the stock's 52-week low/high is $1.00/$20.90.

chart

Pacific Green Technologies, Inc. (PGTK)

InvestorSoup, SuperStockTips, Stock Preacher, Equity Observer, Jet-Life Penny Stocks, SMS Penny Picks, Beacon Equity Research, eliteotc, Penny Stocks Finder, Value Penny Stocks, WINNINGOTC, TryBestPennyStocks, Wall Street Mover, Journal Transcript, Penny Stock Craze, SmallCapAllStars, The Street, and Wall Street Beauties reported on Pacific Green Technologies, Inc. (PGTK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pacific Green Technologies, Inc. centers on addressing the world’s need for cleaner and more sustainable energy. The Company’s strategy is to build, by way of organic development and acquisition, a portfolio of patented competitive progressive technologies designed to meet increasingly stringent environmental standards. Pacific Green Technologies China Limited (PGTC) is a subsidiary of Pacific Green Technologies, Inc. OTCQB-listed, Pacific Green Technologies is headquartered in San Jose, California.

The Company has its Envi-Marine™ system - a seawater scrubber. Envi-Marine™ takes an alternative approach to seawater scrubbing through using the Envi-Clean™ innovative turbulent scrubbing head to provide interactive contact between the seawater and the exhaust gas in a turbulent zone containing a high amount of surface area for gas/liquid absorption.

Pacific Green’s ENVI-Clean™ is a patented Emissions Control System. The design of it is to remove pollutants from flue gases. ENVI-Clean™ is suitable for the removal of acid gases and particulate matter from high volume processes.

Furthermore, the ENVI-Pure™ system is a refined version of the ENVI-Clean™ system, designed to remove a broader array of contaminants with very high efficiency as required by Waste to Energy (WtE) and Biomass power plants.

Pacific Green Technologies China Limited (PGTC) has a Commercial Joint Venture Agreement (JV) with POWERCHINA SPEM Co., Limited. The JV Agreement sets out the terms for PGTC and POWERCHINA SPEM to co-operate exclusively in China for 10 years to develop the ENVI-Clean™ and ENVI-Pure™ emission control system to become the market leader in the Coal Fired Power, Steel Works, Cement Works, and Waste to Energy industry sectors.

Pacific Green Technologies previously signed a Memorandum of Understanding (MOU) with POWERCHINA SPEM Co., Limited to incorporate a new company. Pacific Green will own 50.1 percent and POWERCHINA SPEM 49.9 percent. At first, the jointly owned company will market Pacific Green's patented ENVI-Systems™ Technology for removal of noxious gases. It will subsequently look to acquire licenses for more complementary technologies to market in China and Southeast Asia.

This past April, Pacific Green Technologies confirmed that its wholly-owned subsidiary Pacific Green Marine Technologies Limited signed an agreement with Union Maritime Limited to supply seven ENVI-Marine™ Exhaust Gas Scrubbing Systems for Union Maritime's four new 45,999 DWT Chemical Tankers being built by Hyundai Marine Division in South Korea and three 64,000 DWT Bulk Carriers being built by COSCO in China.

The ENVI-Marine™ Exhaust Gas Scrubbers will be manufactured through Pacific Green’s JV with Chinese Government owned PowerChina SPEM and installed in different yards in Asia. The vessels will begin to be delivered this fall, with the last being delivered in early 2020.

Pacific Green Technologies, Inc. (PGTK), closed Tuesday's trading session at $1.8505, up 8.95%, on 100 volume with 1 trade. The average volume for the last 60 days is 1,900 and the stock's 52-week low/high is $0.25/$2.00.

chart

Delcath Systems, Inc. (DCTH)

OTC Markets, Barchart, Invest.com, Morningstar, Stock News Journal, Stocktwits, SuperStockScreener, StocksGallery, 4-Traders, TradingView, MarketWatch, and Insider Financial reported on Delcath Systems, Inc. (DCTH), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Delcath Systems, Inc. is an interventional oncology Company centered on the treatment of primary and metastatic liver cancers. Its investigational product is Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The design of this product is to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Delcath Systems has its corporate office in New York, New York. The Company lists on the OTCQB.

Delcath Systems has supported clinical research of liver directed high dose chemotherapy in patients with metastatic ocular and cutaneous melanoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and hepatocellular carcinoma. Liver directed high dose chemotherapy uses percutaneous hepatic perfusion (PHP) to deliver concentrated doses of a chemotherapeutic agent directly to the liver.

The Company’s system has been commercially available in Europe since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a broad array of cancers of the liver.

Delcath is working on advancing its clinical programs of its unique Melphalan/HDS. Moreover, it is working to boost commercialization efforts for CHEMOSAT in Europe. It continues its focus on the clinical trials, which consist of the Clinical Development Program (CDP).

The Company has begun an international Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM). It plans to start a worldwide registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the United States.

Delcath Systems announced in May that it started its pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). Duke Medical Center in Durham, North Carolina is the first cancer center to open for patient enrolment.  Dr. Sabino Zani is serving as the principal investigator for the trial in the United States. Dr. Zani is a surgical oncologist with Duke Medical Center.

In late July, Delcath Systems announced that it filed an amendment with the FDA to revise the protocol for its Phase 3 clinical trial in ocular melanoma liver metastases. With this amendment, the trial, now entitled, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma, will enroll 80 patients with ocular melanoma metastatic to the liver.

On the whole, the enrollment of 80 patients represents a 66 percent reduction in trial size from the previous randomized trial that required 240 patients to reach statistical significance. Patients presently enrolled in the Melphalan/HDS arm of the trial under the prior randomized protocol will continue to be treated and evaluated as part of the amended trial. With the amendment, Delcath Systems anticipates completing trial enrollment by the end of the first half of 2019.

Yesterday, Delcath Systems announced that patient enrollment has started under the amended protocol for its registration trial in ocular melanoma liver metastases. Stanford University Medical Center is the first trial site to obtain Institutional Review Board (IRB) approval for the amended protocol. The Center is open to patient enrollment.

Today, Delcath Systems announced that the first patient was enrolled under the amended protocol for its registration trial in ocular melanoma liver metastases. Stanford University Medical Center is the first trial site to enroll a patient under the amended protocol.

Delcath Systems, Inc. (DCTH), closed Tuesday's trading session at $1.93, down 9.39%, on 13,378 volume with 89 trades. The average volume for the last 60 days is 8,222 and the stock's 52-week low/high is $1.22/$27125.00.

chart

Liquidmetal® Technologies, Inc. (LQMT)

Greenbackers, SmallCapVoice, PennyStocks24, Pennybuster, Marketbeat.com, Jason Bond, Promotion Stock Secrets, Penny Pro, Winston Small Cap, Wall Street Mover, SuperNova Elite, Wealth Daily, PennyStocks Forever, and Penny Stocks VIP reported on Liquidmetal Technologies, Inc. (LQMT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Liquidmetal® Technologies, Inc. is the foremost developer of bulk alloys, which utilize the performance advantages that amorphous alloy technology provides. Amorphous alloys are unique materials distinguished by their ability to retain a random structure when they solidify. This is in comparison to the crystalline atomic structure that forms in ordinary metals and alloys. Liquidmetal® Technologies has its headquarters in Rancho Santa Margarita, California, where it also has its Manufacturing Center of Excellence. The Company’s shares trade on the OTC Markets.

Liquidmetal Technologies is the first company to produce amorphous alloys in commercially viable bulk form. This is enabling critical improvements in products across a wide array of industries.

Liquidmetal has two to three times the strength of titanium and stainless steel. It undergoes processing alike to plastics on the Company's proprietary Liquidmetal molding machines. The Company’s class of patented alloys and processes form the foundation of high performance materials used in a broad spectrum of medical, military, consumer, and industrial, and sporting goods products.

Liquidmetal is processed and solidified in a vitreous or amorphous state (frozen liquid). Liquidmetal® Technologies’ alloys are, in many cases, stronger, harder, more elastic, and more wear and corrosion resistant than typically used high-performance alloys.

The Company’s "bulk" amorphous alloys possess advantages normally associated with plastics. These include the ability to undergo molding into precision, complex, as well as highly finished products. Liquidmetal® Technologies controls the Intellectual Property (IP) rights with greater than 70 U.S. patents.   

Liquidmetal® Technologies and the University of Southern California’s M.C. Gill Composites Center are working in tandem to develop an advanced manufacturing process to produce large-scale amorphous metal and fiber laminate sheets for space applications. The work is funded by a NASA SBIR (Small Business Innovation Research) Phase I contract addressing solicitation topic number Z2.01, “Cross cutting advanced manufacturing process for large scale bulk metallic glass systems for aerospace applications.”

Professor Lugee Li, Chairman and Chief Executive Officer at Liquidmetal® Technologies was presented with an Excellence Award from the International Magnesium Association (IMA) at the 2017 World Magnesium Conference, which took place in Singapore on May 21-23, 2017. This Excellence Award was presented to Professor Li in recognition of a new automotive cast design for structural portions of automotive closure panels (side doors, lift gates, hoods, trunk lids) where his innovative, novel, and creative design and development of magnesium demonstrated considerable advances over existing practice.

In Q2 2017, ended June 30, 2017, Liquidmetal® Technologies received two hot crucible amorphous metal molding machines from its licensing partner Eontec Ltd. The machines permit the production of amorphous alloy parts, which are up to three times larger and one-third the cost of established technologies. The Company also continued the build out of its new manufacturing facility in Q2, which it bought in February of this year.

Liquidmetal Technologies, Inc. (LQMT), closed Tuesday's trading session at $0.205, up 4.43%, on 1,531,474 volume with 182 trades. The average volume for the last 60 days is 1,143,291 and the stock's 52-week low/high is $0.161/$0.44.

chart

SANUWAVE Health, Inc. (SNWV)

Marketbeat.com, RedChip, TopPennyStockMover, SmallCapVoice, PennyStocks24, OTC Stock Review, Penny Stock Rumble, Streetwise Reports, The Green Baron, Greenbackers, OTCJournal, FeedBlitz, AllPennyStocks, OTC Stock Review, Explicit Penny Picks, Free Investment Report, Free Penny Alerts, Gladiator Stocks, InsidersLab, KillerPennyStocks, and Ox of Wallstreet reported on SANUWAVE Health, Inc. (SNWV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

SANUWAVE Health, Inc. is a shock wave technology business. Its initial focus is on the development and commercialization of patented non-invasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE Health researches, designs, manufactures, markets and services its products internationally. SANUWAVE Health is headquartered in Suwanee, Georgia.

The Company applies its patented Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions. Its portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses. This produces new vascularization and microcirculatory improvement. This helps in restoring the body's normal healing processes and leads to regeneration of tissue.

SANUWAVE’s lead product candidate for the global wound care market, dermaPACE®, is CE marked across Europe. It has Canada, Australia, and New Zealand device license approval for the treatment of skin and subcutaneous soft tissue. In the U.S., dermaPACE is now under the Food and Drug Administration's (FDA's) de novo petition review process for the treatment of diabetic foot ulcers. Diabetic foot ulcer treatment additionally has approval in South Korea.

SANUWAVE’s belief is that it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) via its U.S. Class III PMA approved OssaTron® device, and also stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the use of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific. Moreover, there are license/partnership opportunities for the Company’s shock wave technology for non-medical uses. This includes energy, water, food, and industrial markets.

In December of 2016, SANUWAVE Health announced that it, in partnership with Ortho-Medico, a member of B&Co, Herzele, Belgium, is sponsoring ongoing clinical investigation on diabetic foot ulcers (DFU). The trial will be conducted by the VUB (Free University of Brussels) and UZ Brussel (University Hospital).

Previous work in 2015 at this hospital found that DFU patients, treated in-home with the dermaPACE system, responded positively to the treatment. The trial will take the home-care procedures, used in a limited basis, and extend them to a randomized, controlled trial of 100 subjects. The intention of the trial is to compare the effectiveness of in-home treatment of DFUs utilizing dermaPACE versus in-home treatment of DFUs using standard of care only. The trial will help to provide evidence that dermaPACE can be used outside the clinical setting and increase the potential for increased sales in Europe.

In February 2017, SANUWAVE Health announced that the U.S. Patent and Trademark Office (USPTO) issued SANUWAVE patent number 9,566,209 titled "Shock Wave Electrodes with Fluid Holes", which has an expiration date on June 21, 2033. The patent relates to a new construction of the spark gap electrodes employed to generate acoustic pressure shock waves in the Company’s devices that allows a longer useful life for the applicators.

Recently, SANUWAVE Health announced that it is entering into a Memorandum of Understanding (MOU) with eKare, Inc. This is to develop novel wound care analysis and management solutions. Linking SANUWAVE's dermaPACE® wound treatment device with eKare's inSight® 3D wound imaging and analytics system, the two companies will work to produce the industry's most complete wound management solution. eKare’s commitment is to the design and development of wound assessment solutions utilizing the most contemporary machine intelligence, computer-vision, as well as mobile technology.

SANUWAVE Health, Inc. (SNWV), closed Tuesday's trading session at $0.265, up 1.92%, on 239,275 volume with 52 trades. The average volume for the last 60 days is 128,455 and the stock's 52-week low/high is $0.095/$0.6419.

chart

Zynex, Inc. (ZYXI)

SmarTrend Newsletters, FeedBlitz, BUYINS.NET, TaglichBrothers, Zacks, FNNO Newsletters, Daily Markets, and SmallCapVoice reported earlier on Zynex, Inc. (ZYXI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Zynex, Inc. is a medical technology company listed on the OTC Markets Group’s OTCQB. The Company specializes in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac and blood volume monitoring. Furthermore, Zynex is developing a new blood volume monitor for use in hospitals and surgery centers.  Established in 1996, Zynex is based in Lone Tree, Colorado.

The Company markets and sells its own design of electrotherapy medical devices utilized for pain management and rehabilitation. In addition, Zynex markets and sells its proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients.  Its product lines are completely developed, Food and Drug Administration (FDA)-cleared, and commercially sold globally.  Zynex engineers, manufactures, markets and sells its own design of medical devices in three subsidiaries.

Zynex Medical is a provider of electrotherapy products for home use. Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals. Zynex NeuroDiagnostics develops devices for EMG and EEG diagnostic purposes in the neurology clinic markets.

Zynex announced in March of 2015 that it submitted a Pre-Submission application to the FDA for its non-invasive Blood Volume Monitor, CM-1500. Zynex’s belief is that this will be the first device to provide an indication of fluid balance and blood loss in the operating room or potential post-surgical internal bleeding in recovery.

The Company announced in September of 2015 that its wholly-owned subsidiary, Zynex Monitoring Solutions, filed an application with the FDA pursuant to Section 510(k) of the Food, Drug and Cosmetic Act for clearance of its new CM-1500 monitoring device.

This past June, Zynex announced the appointment of Mr. Dan Moorhead as its Chief Financial Officer (CFO). Mr. Moorhead has more than two decades of experience in an array of finance roles serving private and public companies. He is a CPA (Certified Public Accountant) and holds a B.B.A. in Accounting from the University of Northern Colorado.

Also in June, Zynex announced that ColoradoBiz Magazine recognized the Company in Top100 Public Companies in its May/June 2017 issue. Zynex was ranked 90th on 2016 revenue of $13.3 million. This is up from 93rd in 2015 on $11.6 million in revenue. The Company earlier announced estimated Q2 2017 revenue of $3.8 million and EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) of $650,000.

Zynex, Inc. (ZYXI), closed Tuesday's trading session at $3.37, up 7.32%, on 37,775 volume with 61 trades. The average volume for the last 60 days is 32,029 and the stock's 52-week low/high is $1.09/$5.50.

chart

The QualityStocks Company Corner

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that the Company has been selected as a finalist in the New Mobility World (NMW) Lab18 Startup Challenge. Foresight has been selected from more than 100 applicants from 29 countries, as one of four of the most promising mobility startups to reach the final round.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $2.91, up 8.38%, on 19,396 volume with 109 trades. The average volume for the last 60 days is 55,928 and the stock's 52-week low/high is $2.44/$8.20.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQB: ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF).

VIVO Cannabis Inc. (TSX-V: VIVO, OTCQB: ABCCF) (“VIVO” or the “Company”) is pleased to announce that it has completed an agreement with the Ontario Cannabis Store (“OCS”) to supply the province with high-quality cannabis products.  Under the terms of the agreement, VIVO will supply the Ontario market with 16 cannabis products to meet demand in the adult-use recreational cannabis market, set to open on October 17, 2018.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQB: ABCCF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (ABCCF), closed the day's trading session at $1.03, up 3.00%, on 402,228 volume with 452 trades. The average volume for the last 60 days is 222,581 and the stock's 52-week low/high is $0.6574/$3.2929.

Recent News

chart

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

California is now home to the largest legal cannabis market in the world. A pioneer of medical marijuana, which it legalized in 1998, the state has gone a step further by legalizing adult use of marijuana as of January 1, 2018. As a result, sales, already accounting for one-third of legal cannabis sales revenues in the U.S., are projected to reach $4.3 billion in 2018 and continue to grow to $6.5 billion by 2020, according to Arcview Research & New Frontier Data. But such rapid growth won’t be possible unless the industry can attract funding, which means that the services provided by specialty financing company FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) will likely be in high demand.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.1936, up 3.25%, on 16,300 volume with 10 trades. The average volume for the last 60 days is 45,866 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

chart

SinglePoint, Inc. (OTCQB: SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint Inc. (OTC:SING) today announces its status as a fully reporting company by way of filing Form 10-12G and reports year-over-year improvements for the second quarter and six months ended June 30, 2018. Second-quarter revenues increased nearly 100% compared to the same quarter of 2017. In the first six months of 2018, SinglePoint recorded over $500,000 in revenue as a result of several successful acquisitions. The company hopes to maintain this growth trend through its current business model.

SinglePoint, Inc. (OTCQB: SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.05, up 2.34%, on 5,195,237 volume with 201 trades. The average volume for the last 60 days is 6,250,759 and the stock's 52-week low/high is $0.0235/$0.133.

Recent News

chart

CytoDyn Inc. (OTCQB: CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) recently announced exciting progress (http://nnw.fm/Md2hq) in the development of PRO 140 (leronlimab), its novel humanized CCR5 monoclonal antibody, which has multiple therapeutic indications including treating HIV, cancer and inflammatory conditions.

CytoDyn Inc. (OTCQB: CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.585, up 1.21%, on 546,071 volume with 121 trades. The average volume for the last 60 days is 317,607 and the stock's 52-week low/high is $0.40/$0.836.

Recent News

chart

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (Frankfurt: GHG) (the “Partners”) are pleased to provide an update on their CBD hemp farming joint venture in New Brunswick, Canada (the “Project”). Also today, the company was featured in an article on the increasing demand for Cannabidiol (CBD) and Hemp based products, which is expected to push both markets into new territories in terms of sales value in the coming years.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0279, up 1.45%, on 7,443,665 volume with 368 trades. The average volume for the last 60 days is 7,910,356 and the stock's 52-week low/high is $0.022/$0.0728.

Recent News

chart

Zenergy Brands, Inc. (OTC: ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

The German pop group Snap! may have been singing for Zenergy Brands, Inc. (OTC: ZNGY) with its 1990 hit ‘I’ve Got the Power’, for the Texas-based company undoubtedly has. Operating in the emerging smart energy, conservation and utility markets, Zenergy provides a suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom lines.

Zenergy Brands, Inc. (OTC: ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.0006, even for the day, on 6,267,832 volume with 19 trades. The average volume for the last 60 days is 21,649,527 and the stock's 52-week low/high is $0.0005/$0.03.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) is pleased to announce it has signed a definitive agreement to acquire 100% of the issued and outstanding shares of privately-held HemPoland in an immediately accretive cash and share transaction. Also today, CannabisNewsWire released a report on the company detailing how TGODF is preparing to reward its shareholders and boost its bottom line by spinning off a new corporation that will focus on “the acquisition and development of worldwide opportunities,” according to a recent news release (http://cnw.fm/4evyA).

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $3.98, off by 1.41%, on 254,892 volume with 766 trades. The average volume for the last 60 days is 246,643 and the stock's 52-week low/high is $2.784/$7.565.

Recent News

chart

DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

DPW Holdings, Inc. (NYSE American: DPW) (the “Company”) a diversified holding company, today submitted its Quarterly Report on Form 10-Q reporting financial results for its second quarter ended June 30, 2018. Second quarter gross revenue was $7.4 million, a 309 percent increase from $1.8 million in the second quarter of 2017 and 43 percent increase from $5.2 million in the first quarter 2018.

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

  • The highest efficiency and highest density power converters and inverters
  • Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
  • Very high-frequency filters
  • Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

  • Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
  • Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
  • Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
  • Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
  • Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

  • Achieve compounded annual revenue growth of 25-35%
  • Achieve compounded annual net Income growth of 5%
  • Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.395, off by 6.82%, on 1,418,639 volume with 1,855 trades. The average volume for the last 60 days is 24,257 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

chart

Medical Cannabis Payment Solutions (OTC: REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

The expedited growth and demand of legal marijuana operations has made it difficult for dispensaries to manage all aspects of their operations. There are many moving parts that go into remaining compliant with FinCEN and the Cole Memo, maintaining safety in the handling of funds for a traditionally cash only industry and managing customer satisfaction and quality control. Medical Cannabis Payment Solutions (OTC: REFG) is providing clients an end-to-end management system called Green. Merchant clients can register online for a total banking solution for cannabis-related businesses.

Medical Cannabis Payment Solutions (OTC: REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.039, even for the day, on 355,962 volume with 41 trades. The average volume for the last 60 days is 377,571 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News

chart

Cannabis Strategic Ventures, Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures (OTC:NUGS) was featured today in an article from CannabisNewsWire discussing the quickly rising demand for Cannabidiol (CBD) and Hemp based products is expected to push both markets into new territories in terms of sales value in the coming years as Companies race to get involved on any level. Also today, a report featuring NUGS was released by CannabisNewsWire detailing how the company is out to take a slice of the billion-dollar Asian Nutraceutical pie. The company recently cut a deal to acquire the Fitamins CBD brand (http://cnw.fm/LC8cm).

Cannabis Strategic Ventures, Inc. (OTC: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $2.50, off by 9.09%, on 159,324 volume with 368 trades. The average volume for the last 60 days is 33,043 and the stock's 52-week low/high is $0.031/$7.13.

Recent News

chart

GTX Corp (OTC: GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp (GTXO).

GTX Corp (OTCBB: GTXO) (“the Company”), a pioneer in the field of wearable GPS human and asset tracking systems and wandering assistive technology, today announced a summary for the second quarter ended June 30, 2018. Also today, NetworkNewsWire released a report on the company detailing how GTXO has partnered with George Mason University’s College of Health and Human Services (“Mason”) in an important study using the company’s flagship GPS SmartSole® and tracking technology platform (http://nnw.fm/4MohI).

GTX Corp (OTC: GTXO), a For Profit For Purpose company, designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business. Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (http://nnw.fm/mrcV2), there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

  • Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
  • Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
  • Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
  • P.E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
  • GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp (GTXO), closed the day's trading session at $0.0661, off by 4.20%, on 164,997 volume with 23 trades. The average volume for the last 60 days is 18,569 and the stock's 52-week low/high is $0.055/$0.6675.

Recent News

chart

GreenBox POS, LLC (OTCQB: GRBX)

The QualityStocks Daily Newsletter would like to spotlight GreenBox POS, LLC (GRBX).

GreenBox POS, LLC’s (OTCQB: GRBX) acquisition of Sky Mids Technologies brings together two companies that have already worked together in payments processing, ensuring a quick start to their transition (http://nnw.fm/Dvk3u). It also brings to GRBX Sky’s book of transactional business, capable of processing greater than $1 billion annually, which will be added to GRBX upon review. GRBX has already commenced onboarding Sky’s book of business onto its infrastructure.

GreenBox POS, LLC (OTCQB: GRBX) is a hardware and software technology company that builds customized payment solutions in different industries. The company is headquartered in San Diego, California, with offices in Seattle, Wash.; Las Vegas, Nevada; and Vancouver, British Columbia, Canada. GreenBox, which has been awarded five provisional patents for its blockchain-based technology, delivers a fully integrated, intuitive, easy-to-use, point of sale (POS) system for a variety of businesses across a multitude of different market sectors.

GreenBox develops all software in-house and with international subsidiaries, which allows the company to provide individualized electronics modifications in partnership with different vendors. Custom POS machines are available as an upgrade from existing solutions currently in use. First-time merchants can also take advantage of custom-built kiosk machines powered by blockchain technology, complete with e-wallet integration downloadable via Android or iOS apps, or via installed cash-loading kiosks.

GreenBox develops POS (point of sale) software and hardware solutions; DEL (delivery app, APIs to POS and PAY); PAY (payment app, providing financial APIs to all other components); and KIOSK (deposit, cash and E-wallet management). The following flagship products, services and custom hardware are currently available:

  • QuickCard – the QuickCard kiosk handles all cash issues, both for cashless operations and for legacy cash; performs direct and immediate deposits from cash to blockchain and confirms bank account availability within minutes. Accepts cash, debit/credit cards, or ACH directly to most banks while settling funds instantly. All records are stored securely on blockchain. No faster deposit solution is available in the regular and non-traditional banking systems (unless depositing cash directly into a cash machine connected to a bank branch).
  • POS Solutions – GreenBox software, developed in-house and with international subsidiaries, features operational compliance, financial audit prep, expense tracking, tax payments, register-specific features, and data fidelity controls (backup/restore, cloud security, privacy, etc.). GreenBox POS software is fully integrated with Del and Pay Systems and features front register mode and back-end admin mode, in addition to in-admin mode to manage employees, vendors, expenses, taxes and compliance. All records are stored on blockchain with data reliably secured and protected.
  • LOOPZ – This delivery software solution offers service dispatcher back-end technology with manual and automatic modes. The software is uniquely designed to be effectively utilized for mobile delivery service operations with full autonomous dispatch capabilities. LOOPZ provides the following features: two mobile apps (driver and consumer) running on Android and IOS; direct reporting to point of sale inventory and use of pay for instant settlements; separate escrow setup for tips and merchant sale; all data and information is securely hosted on a blockchain platform.

The management team at GreenBox includes CEO Fredi Nisan, who comes from the POS and merchant services business sector. He recently completed a successful exit in the POS and ERP business, which he founded and managed through the exit. Joining Nisan is Ben Errez, executive vice president, who comes from the investment, consulting and big software and hardware industries. His previous executive roles include positions at Microsoft (including engineering management of Microsoft Office for complex scripts); IBM (with which he had an exit); and Intel. Errez has also consulted the world’s biggest private economy, World Trade Center, on payment systems, security, reliability and privacy of software and hardware development.

GreenBox POS, LLC (GRBX), closed the day's trading session at $0.8525, off by 13.89%, on 61,380 volume with 56 trades. The average volume for the last 60 days is 53,389 and the stock's 52-week low/high is $0.017/$1.95.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.